Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Works matching IS 01145916 AND DT 2001 AND VI 24 AND IP 2
Results: 7
1
2
What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects?
- Published in:
- Drug Safety, 2001, v. 24, n. 2, p. 75, doi. 10.2165/00002018-200124020-00001
- By:
- Publication type:
- Article
3
Thalomid[sup ®] (Thalidomide) Capsules: A Review of the First 18 Months of Spontaneous Postmarketing Adverse Event Surveillance, Including Off-Label Prescribing.
- Published in:
- Drug Safety, 2001, v. 24, n. 2, p. 87, doi. 10.2165/00002018-200124020-00002
- By:
- Publication type:
- Article
4
Safety of antihistamines in children.
- Published in:
- 2001
- By:
- Publication type:
- journal article
5
Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting.
- Published in:
- 2001
- By:
- Publication type:
- journal article
6
Incompleteness of lamotrigine data.
- Published in:
- 2001
- By:
- Publication type:
- Letter
7
Incompleteness of Lamotrigine Data: The Author's Reply.
- Published in:
- Drug Safety, 2001, v. 24, n. 2, p. 155, doi. 10.2165/00002018-200124020-00006
- By:
- Publication type:
- Article